Physician profile
John Randazzo
NPI 1962922047
$243.64
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $36.15 · 2021: $127 · 2022: $80.89.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $34.31 | 2020-2021 | |
| Melinta Therapeutics, LLC | $28.06 | 2021 | |
| Nevro Corp. | $26.73 | 2022 | |
| Nabriva Therapeutics, Plc | $26.40 | 2021 | |
| Misonix INC | $21.08 | 2020 | |
| Stryker Corporation | $19.82 | 2022 | |
| Smith+Nephew, INC. | $19.49 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $18.52 | 2022 | |
| Abbvie INC. | $16.77 | 2021 | |
| Horizon Therapeutics Plc | $16.64 | 2021 | |
| Osteomed LLC | $15.82 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Randazzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.